In female mice with bleomycin-induced pulmonary fibrosis, oral Liquiritigenin dose-dependently reduced mortality compared with the pulmonary fibrosis model group. Liquiritigenin also significantly reduced alveolar wall thickening and extracellular matrix deposition compared with the pulmonary fibrosis model group, with the most pronounced effect at 100 mg/kg. In male BALB/c mice with CP-induced AKI, intraperitoneal Liquiritigenin significantly reduced serum creatinine and urea nitrogen levels compared with the model group. [2,3]
Mortality in Bleomycin-Induced Pulmonary Fibrosis
Animal study · Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice [2]
Female mice with bleomycin-induced pulmonary fibrosis received oral Liquiritigenin at 25 mg/kg, 50 mg/kg, or 100 mg/kg. Liquiritigenin dose-dependently reduced mortality compared with the pulmonary fibrosis model group.
Conditions shared by the study groups
- Route
- oral
- Treatment course
- on days 15–28
- Vehicle
- 0.9% saline
- Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg
- Model: Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice
Methods and source locations
Compound reported in the paper: Liquiritigenin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Experimental animals (S1, S3, S4, S5); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S81); Fig. 1 legend (S131)
The survival curve of mice was recorded.: The survival curve of mice was recorded.; comparator: pulmonary fibrosis model group (intratracheal bleomycin on day 0 + oral 0.9% saline on days 15–28) — Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S81); Fig. 1 legend (S131)
Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg · Materials and methods > Experimental animals (S5); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S81)
Serum Creatinine and Urea Nitrogen in CP-Induced AKI
Animal study · Male BALB/c mice; CP-induced AKI mice model; n = 9 mice/group [3]
Male BALB/c mice with CP-induced AKI received Liquiritigenin by intraperitoneal injection at 15 mg/kg body weight/day. Liquiritigenin significantly reduced serum creatinine and urea nitrogen levels compared with the model group.
Conditions shared by the study groups
- Route
- intraperitoneal injection
- Treatment course
- once/day for a continuous 2 days, and the first injection was at 30 min prior to CP treatment; after 72 h post-injection of CP solution
- Vehicle
- 0.5% DMSO in 0.9% NaCl injection
- Liquiritigenin 15 mg/kg body weight/day
- Model: Male BALB/c mice; CP-induced AKI mice model; n = 9 mice/group
Methods and source locations
Compound reported in the paper: Liquiritigenin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. Liquiritigenin Protected against CP-Induced AKI in Mice (S3); 4. Materials and Methods > 4.2. Experimental Animals (S31, S34, S37, S39); Figure 1 legend (S91)
Serum creatinine levels: Serum creatinine levels; comparator: model group — 2. Results > 2.1. Liquiritigenin Protected against CP-Induced AKI in Mice (S3); Figure 1 legend (S91)
Liquiritigenin 15 mg/kg body weight/day · 2. Results > 2.1. Liquiritigenin Protected against CP-Induced AKI in Mice (S3); 4. Materials and Methods > 4.2. Experimental Animals (S34, S37, S39)
Alveolar Wall Thickening and Extracellular Matrix Deposition
Animal study · Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice [2]
Female mice with bleomycin-induced pulmonary fibrosis received oral Liquiritigenin at 25 mg/kg, 50 mg/kg, or 100 mg/kg. Compared with the pulmonary fibrosis model group, Liquiritigenin significantly reduced alveolar wall thickening and extracellular matrix deposition, with the most pronounced effect at 100 mg/kg.
Conditions shared by the study groups
- Route
- oral
- Treatment course
- on days 15–28; On day 29, the mice were euthanized for lung tissue collection.
- Vehicle
- 0.9% saline
- Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg
- Model: Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice
Methods and source locations
Compound reported in the paper: Liquiritigenin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Experimental animals (S1, S3, S4, S5, S9); Materials and methods > Histological analysis (S11); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S80, S81); Fig. 1 legend (S129)
Lung morphology and ECM deposition were evaluated through HE and Masson staining.: Lung morphology and ECM deposition were evaluated through HE and Masson staining.; comparator: pulmonary fibrosis model group (intratracheal bleomycin on day 0 + oral 0.9% saline on days 15–28) — Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S80); Fig. 1 legend (S129)
Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg · Materials and methods > Experimental animals (S5, S9); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S80)